LeserbriefKommentar
Skin Cancer after Ruxolitinib or Belumosudil
New England Journal of Medicine · 2023
DOI: 10.1056/nejmc2309427 ↗Kurz gefasst
Leserbrief in der Zeitschrift New England Journal of Medicine, 2023. Verfasst von Chrysalyne D Schmults. Beteiligte Einrichtung: Brigham and Women's Hospital, Boston, MA. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Skin Neoplasms. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Carcinoma, Squamous CellSkin NeoplasmsHumansAcetamidesNitrilesPyrazolesPyrimidines
Substanzen
AcetamidesbelumosudilruxolitinibNitrilesPyrazolesPyrimidines
Autor:innen und Institutionen
- Brigham and Women's Hospital, Boston, MA.
Zitieren
APA
Schmults, C. D. (2023). Skin Cancer after Ruxolitinib or Belumosudil. New England Journal of Medicine. https://doi.org/10.1056/nejmc2309427
Vancouver
Schmults CD. Skin Cancer after Ruxolitinib or Belumosudil. New England Journal of Medicine. 2023. doi:10.1056/nejmc2309427
BibTeX
@article{Schmults2023,
author = {Schmults, Chrysalyne D},
title = {Skin Cancer after Ruxolitinib or Belumosudil},
journal = {New England Journal of Medicine},
year = {2023},
doi = {10.1056/nejmc2309427}
}
EUVIMED